Biogen has launched a trio of trials to test its new drug candidate for spinal muscular atrophy (SMA), salanersen, which aims to be a more convenient successor to the company’s approved SMA therapy Spinraza (nusinersen). Salanersen would need to be administered just once per year. The biotech…
Treatment with Spinraza (nusinersen) led to sustained improvements in motor function in adults with spinal muscular atrophy (SMA), and showed a manageable safety profile, according to a nationwide study in South Korea. Among 19 adults, researchers reported meaningful gains in motor function scores — particularly in knee bending and…
Discussion
To its credit, “The Beauty,” a new sci-fi, body-horror miniseries from Ryan Murphy, co-creator of “American Horror Story” and other acclaimed projects, dives deeper into the topic of genetic editing and disability than most sci-fi shows I’ve seen. Typically, as in “Jurassic World: Rebirth,” genetic editing is framed either as…
Scholar Rock plans to resubmit its application to the U.S. Food and Drug Administration (FDA) seeking approval for apitegromab, an investigational muscle-strengthening therapy for spinal muscular atrophy (SMA). The submission is contingent on the successful FDA reinspection of a manufacturing site operated by the company’s third-party fill-finish…
Discussion
How can I possibly show the deep appreciation that I have for the caregivers in my life with spinal muscular atrophy (SMA)? This is a question that burdens me often when I feel weak, inadequate, and overwhelmed by their compassion. But today is Caregiver Appreciation Day, so…
Next week, researchers, clinicians, industry leaders, and families will gather at the 2026 MDA Clinical & Scientific Conference, hosted by the Muscular Dystrophy Association (MDA), to discuss the latest advances in neuromuscular disease research and care. Ahead of the event, Bionews, the parent company of this site, sat…
Get regular updates to your inbox.
